AcuraStem, Inc.

AcuraStem’s development candidate AS-202 demonstrates excellent safety and potency in preclinical models representing diverse forms of ALS

AS-202 demonstrates excellent safety and potency as a potential treatment for ALS, with significant improvements in motor function and survival in an aggressive TDP-43 mouse model. The data also shows that AS-202 is a potent PIKFYVE suppressor with no significant off-target effects.

SourceAcuraStem, Inc.·TypeExperimental study·DateDec 15, 2021

AcuraStem triggers $3M phase II Fast Track SBIR Grant

AcuraStem has secured a $3 million Phase II funding for its AS-1 Program, a lead small molecule program targeting amyotrophic lateral sclerosis (ALS). The award allows the company to accelerate the AS-1 program and expand its iNeuroRx technology platform.

SourceAcuraStem, Inc.·DateOct 23, 2019

AcuraStem receives fast-track SBIR grant

AcuraStem has been awarded a $3.7 million SBIR grant to continue research on a small molecule therapeutic for ALS, utilizing induced motor neuron cellular models and precision platform iNeuroRx°. The grant supports the development of AS2015, targeting expansion repeats in the C9ORF72 gene.

SourceAcuraStem, Inc.·DateJun 18, 2018